(S)-tert-butyl (2-(2-(2-(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate | 1571096-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (S)-tert-butyl (2-(2-(2-(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate
• 英文别名: tert-butyl N-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]carbamate；(S)-t-butyl (2-(2-(2-(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate
• CAS: 1571096-67-7
• 化学式: C₂₇H₃₇Cl₂N₃O₆S
• 分子量: 602.579
• InChiKey: CXJDEIPXXHFZHW-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  39
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl (2-(2-(2-(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate 在 盐酸 、 氢溴酸 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 26.0h， 生成
  参考文献：
  名称：

  [EN] SOLID FORMS OF TENAPANOR AND METHOD OF PREPARATION OF TENAPANOR
  [FR] FORMES SOLIDES DE TÉNAPANOR ET PROCÉDÉ DE PRÉPARATION DE TÉNAPANOR

  摘要：

  该发明涉及特纳帕诺的固体形式，特别是特纳帕诺游离碱的结晶形式I和固体特纳帕诺盐，以及其制备方法。结晶形式I是已知的特纳帕诺的第一种结晶形式。特纳帕诺的新型固体形式可用于特纳帕诺的纯化和/或在制药组合物中使用。此外，该发明提供了一种经济有效且可扩展的结晶特纳帕诺的制备方法。

  公开号：

  WO2019091503A1
• 作为产物：
  描述：

  tert-butyl N-[2-[2-[2-[[3-[6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]carbamate 在 Chiralpak AD 作用下， 以 乙醇 、 乙腈 为溶剂， 以23%的产率得到(S)-tert-butyl (2-(2-(2-(3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenylsulfonamido)ethoxy)ethoxy)ethyl)carbamate
  参考文献：
  名称：

  [EN] SODIUM-HYDROGEN EXCHANGER 3 INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS DE L'ÉCHANGEUR SODIUM-HYDROGÈNE 3

  摘要：

  本发明涉及一种公式为的钠-氢交换3（NHE3）抑制剂化合物：制备该化合物的药物组合物以及将该化合物用于治疗与升高的钠和/或磷水平相关的某些疾病的用途。

  公开号：

  WO2020231770A1

文献信息

• [EN] COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS DESTINÉS À INHIBER UN ANTIPORT MÉDIÉ PAR NHE DANS LE TRAITEMENT DES TROUBLES ASSOCIÉS À UNE RÉTENTION DE FLUIDE OU À UNE SURCHARGE DE SEL ET DES TROUBLES DU TRACTUS GASTRO-INTESTINAL
  申请人：ARDELYX INC

  公开号：WO2014029984A1

  公开（公告）日：2014-02-27

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：ARDELYX, INC.

  公开号：US20150299131A1

  公开（公告）日：2015-10-22

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗液体潴留或盐过多症状的方法，如心力衰竭（特别是充血性心力衰竭）、慢性肾脏疾病、末期肾脏疾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂引起的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• 苯磺酰胺类化合物及其制备方法和应用
  申请人：江西济民可信集团有限公司

  公开号：CN114805202A

  公开（公告）日：2022-07-29

  本发明公开了苯磺酰胺类化合物及其制备方法和应用，具体地，本发明公开了式(Ⅰ)所示化合物及其药效上可接受的盐，及其用于慢性肾病的治疗。
• Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
  申请人：Ardelyx, Inc.

  公开号：US10385024B2

  公开（公告）日：2019-08-20

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开内容涉及用于治疗与体液潴留或盐负荷过重相关的疾病的化合物和方法，如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病和过氧化物酶体增殖激活受体（PPAR）γ激动剂诱导的体液潴留。本公开还涉及治疗高血压的化合物和方法。本公开还涉及治疗胃肠道疾病的化合物和方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• SODIUM-HYDROGEN EXCHANGER 3 INHIBITOR COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：EP3921308B1

  公开（公告）日：2022-08-03